Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Biopharma Industry News: Update on the Novel Coronavirus
3D, Antivirals, Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, FDA, FDA/Regulatory, Genomics, Laboratory, MERS, Messenger RNA (mRNA) Vaccines, Partnerships, Plasma, R&D, SARS, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), TestsA summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
Japan scientists win backing for work on potential Nipah vaccine
Bat-Borne Diseases, Brain Damage, Coalition for Epidemic Preparedness Innovations (CEPI), Crimean-Congo hemorrhagic fever (CCHF), Deals, Ebola, Epidemics, Genes, India, Lassa Virus, Measles, MERS, Nipah Virus, Outbreaks, R&D, Vaccines, World Health Organization, Zika VirusA global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.